In some aspects, the disclosure relates to a composition including niacinamide and polypodium leucotomos extract, optionally with additional photoprotective ingredients including ascorbic acid, optionally biotin, astaxanthin, bovine collagen peptides, L-glutathionc, hyaluronic acid, and inositol. The composition provides rapid and measurable photoprotection, reducing UV-induced erythema by approximately 60-68% when administered 1- 2 hours prior to UV exposure. Clinical studies demonstrate significant increases in minimal erythema dose (MED) with effects persisting for at least 24 hours following a single oral administration. The composition exhibits excellent formulation characteristics including superior mixability, clarity, and palatability when formulated as a beverage powder.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
In some aspects, the disclosure relates to a composition including niacinamide and polypodium leucotomos extract, optionally with additional photoprotective ingredients including ascorbic acid, optionally biotin, astaxanthin, bovine collagen peptides, L-glutathione, hyaluronic acid, and inositol. The composition provides rapid and measurable photoprotection, reducing UV-induced erythema by approximately 60-68% when administered 1-2 hours prior to UV exposure. Clinical studies demonstrate significant increases in minimal erythema dose (MED) with effects persisting for at least 24 hours following a single oral administration. The composition exhibits excellent formulation characteristics including superior mixability, clarity, and palatability when formulated as a beverage powder.
